Joint Formulary & PAD

Dexamfetamine sulfate - Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Tablets
Associated Icons :
BNF SPC
CD
Restrictions / Comments :
Important

This entry has not yet been reviewed for inclusion on the joint formulary. However, this information has been published due to the ongoing requirement for prescribers to access the shared care agreement and other resources that were in place prior to the launch of the joint formulary.

Please refer to the list of agreed formulations and former traffic light status available on the PAD page (accessed by clicking the drug name).

PAD Profile

ChemicalSubstance :
Dexamfetamine sulfate
Indication :
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Group Name :
Keywords :
Attention Deficit Hyperactivity Disorder
Brand Names Include :
Amfexa
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5

Other Indications

Below are listed other indications that Dexamfetamine sulfate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs.

Committee Recommendations (2)

Shared Care arrangements for children and adolescents with ADHD are in place with Surrey and Borders Partnership NHS Foundation Trust.

Guildford & Waverley, North West Surrey and Surrey Downs have agreed a Locally Commissioned Service (LCS) for practices entering into the shared care agreement with Surrey & Borders Partnership. The LCS supports the provision of an annual physical medication review by the GP (with an annual review by the specialist so that the patient continues to receive a 6-monthly review in accordance with the product license)
See below for a copy of the Shared care with LCS agreement

There is also a non-LCS shared care agreement that is available for all non-LCS participating practices (see shared care agreement below)

Information on management of ADHD medication stock shortages

There are currently supply disruptions affecting various medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD).

A national patient safety alert has been issued and we have been liaising with colleagues both regionally and nationally about the ongoing situation.  We have been advised that centrally they are looking at publishing further guidance but until this is published we have been working with colleagues from Surrey & Borders Partnership NHS Trust and the Local Pharmaceutical Committee to produce the pack below which provides useful information and clinical recommendations about how to manage these shortages.